| Beide Seiten der vorigen RevisionVorhergehende Überarbeitung | |
| mitragyna_speciosa_korth [2018/02/08 05:42] – andreas | mitragyna_speciosa_korth [2025/07/15 06:57] (aktuell) – andreas |
|---|
| [Rosenbaum, Christopher D., Stephanie P. Carreiro, and Kavita M. Babu. "Here today, gone tomorrow… and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines." Journal of Medical Toxicology 8.1 (2012): 15-32] [[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3550220/pdf/13181_2011_Article_202.pdf]] | [Rosenbaum, Christopher D., Stephanie P. Carreiro, and Kavita M. Babu. "Here today, gone tomorrow… and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines." Journal of Medical Toxicology 8.1 (2012): 15-32] [[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3550220/pdf/13181_2011_Article_202.pdf]] |
| |
| | "Neither Mitragyna speciosa nor mitragynine or other alkaloids from the plant are listed in any of the Schedules of the United Nations Drug Conventions. Mitragyna speciosa and/or mitragynine and/or 7-hydroxymitragynine have been reported to be controlled in at least 12 EMCDDA countries. Denmark, Estonia, France, Italy, Latvia, Lithuania, Poland, Portugal, Romania, Finland, Sweden, Turkey. Other countries that control kratom under their narcotic law are Australia, Malaysia, Myanmar and Thailand. New Zealand controls Mitragyna speciosa and mitragynine under its Medicines Amendment Regulations. In the USA, kratom is not controlled though considered as a ’drug of concern’." \\ |
| | [[https://www.euda.europa.eu/publications/drug-profiles/kratom_en|Kratom drug profile (EUDA)]] retrieved 15 July 2025 |
| |
| {{:mitragyna_speciosa.jpg?600}} \\ | {{:mitragyna_speciosa.jpg?600}} \\ |
